Background and Objectives. The REAL/WHO classification constitutes a new tool for the better understanding and treatment of malignant lymphomas. The authors focus on the key features of B-cell lymphomas with an indolent behavior, aiming to contribute to the cross-talk between pathologists and clinicians. Data Sources and Methods. Each lymphoma entity is analyzed on the basis of the most representative contributions in the literature and the authors' experience gained in studying more than 20,000 lymphoid tumors over a 20-year period. Results. Guidelines for diagnosis and areas of interest for future clinico-pathologic studies are identified and discussed. Within this context, selected data obtained by the application of novel markers are presented. Interpreation and Conclusions. The present knowledge and organization of malignant lymphomas now make the development of tailored therapies a feasible goal.
Pileri, S.A., Ascani, S., Sabattini, E., Fraternali-Orcioni, G., Poggi, S., Piccioli, M., et al. (2000). The pathologist's view point. Part I - indolent lymphomas. HAEMATOLOGICA, 85(12), 1291-1307.
The pathologist's view point. Part I - indolent lymphomas
Poggi, S;Leoncini, L;
2000-01-01
Abstract
Background and Objectives. The REAL/WHO classification constitutes a new tool for the better understanding and treatment of malignant lymphomas. The authors focus on the key features of B-cell lymphomas with an indolent behavior, aiming to contribute to the cross-talk between pathologists and clinicians. Data Sources and Methods. Each lymphoma entity is analyzed on the basis of the most representative contributions in the literature and the authors' experience gained in studying more than 20,000 lymphoid tumors over a 20-year period. Results. Guidelines for diagnosis and areas of interest for future clinico-pathologic studies are identified and discussed. Within this context, selected data obtained by the application of novel markers are presented. Interpreation and Conclusions. The present knowledge and organization of malignant lymphomas now make the development of tailored therapies a feasible goal.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1076555